Kyntra Bio Advances Prostate Cancer Drug Trial, Finalizes Roxadustat Phase 3 Protocol
Event summary
- Phase 2 monotherapy trial of FG-3246 for mCRPC on track for interim analysis in 4Q 2026
- Positive combination therapy results with enzalutamide presented at ASCO GU 2026
- Pivotal Phase 3 trial protocol for roxadustat in LR-MDS finalized with FDA feedback
- $100.3M in cash provides runway into 2028
- Q1 2026 revenue up 37% YoY to $3.7M, net loss reduced to $15.1M
The big picture
Kyntra Bio's progress with FG-3246 reinforces the growing interest in CD46-targeting therapies for prostate cancer, while roxadustat's Phase 3 protocol finalization positions it to address unmet needs in lower-risk MDS. The company's extended cash runway provides operational flexibility as it navigates these pivotal clinical milestones. The combination of biomarker-driven oncology development and established anemia treatments creates a diversified pipeline strategy in competitive therapeutic areas.
What we're watching
- Clinical Validation
- Whether FG-3246's interim analysis will confirm its progression-free survival advantage in mCRPC patients
- Regulatory Pathway
- The pace at which roxadustat's Phase 3 trial initiates following FDA protocol finalization
- Commercial Strategy
- How Kyntra Bio will position roxadustat in the U.S. market given its global approvals and partnership structure
Related topics